Innovations in Biomedical Research: The Jane Coffin Childs Fund Announces 2026 Fellows

Jane Coffin Childs Fund Names 2026 Biomedical Research Fellows

The Jane Coffin Childs Memorial Fund for Medical Research has once again displayed its commitment to fostering biomedical research with the announcement of its 2026 fellows. For nearly 90 years, the Jane Coffin Childs Fund (JCC Fund) has been a cornerstone supporter of early-career researchers, empowering them to explore groundbreaking science, particularly in the realms of cancer and human disease.

Selection Process and Research Themes

This year, 32 exceptional postdoctoral fellows were chosen from a competitive applicant pool by the Fund's Board of Scientific Advisors. Candidates were evaluated based on their past research accomplishments, their innovative research proposals, and the quality of their scientific environments and mentors. The research areas covered by the fellows span critical topics such as amyotrophic lateral sclerosis (ALS), autoimmunity, cancer, and sepsis. Noteworthy projects include studies aimed at understanding how tumor cells acquire necessary nutrients, which could lead to new anti-tumor therapies, and investigations into how the body cooperatively defends against bacterial infections to help prevent sepsis.

Sue Biggins, Ph.D., chair of the advisory board, articulated the significance of this year’s cohort. "The 2026 JCC Fellows represent something we all need right now: scientists with the training, the drive, and the imagination to ask questions that the rest of us haven't thought to ask yet," she stated. As a seasoned HHMI Investigator and Director of the Basic Sciences Division of the Fred Hutchinson Cancer Center, Biggins is also a former fellow of the JCC Fund, advocating for the need to recognize such exceptional talent in these challenging times for scientific inquiry.

Funding and Future Opportunities

The JCC Fund has committed nearly $9 million to support this cohort over three years. Financial backing comes not only from the Fund itself but also from partners including the Robertson Foundation, Achelis Bodman Foundation, Coefficient Giving, JJJ Charitable Foundation, The Hope Funds for Cancer Research, Johnson & Johnson, and Merck Research Laboratories. This collaboration reflects a longstanding tradition of philanthropy fueling scientific progress, ensuring that promising researchers can secure funding essential to their work.

Anita Pepper, Ph.D., executive director of the JCC Fund, expressed excitement about the substantial cohort size: "We are thrilled to have our third largest group of fellows since our founding," she said. "The investments made by our philanthropic partners are crucial in catalyzing remarkable scientific careers while having a significant impact on cutting-edge research."

Looking ahead, the next application round for the 2027 cohort will open in October 2026, promising continued support for emerging scientists committed to advancing the boundaries of biomedical knowledge.

The Legacy of the Fund

Founded in 1937 by the Childs Family to honor Jane Coffin Childs’ memory, the JCC Fund has evolved from its initial focus on cancer research to a broader mission supporting fundamental scientific research. Its goal is to deepen our understanding of the underlying causes, treatments, and potential cures for various human diseases. This legacy continues to inspire both current and future generations of researchers.

For more details about the fund, the fellows, and their groundbreaking projects, interested parties can visit the official website at jccfund.org. Here, further insights await regarding the future of biomedical research and the remarkable individuals steering its course.